Request Information

Pharmatest is very excited to participate in AACR virtual meeting II on June 22-24. Registration for this year’s Meeting is free!

Please meet our Team attending AACR 2020 and ready to answer any of your questions regarding our services. Unfortunately, we won't be able to meet you in person but please contact us to arrange a virtual discussion with our experts in oncology.

The following presentations will be available on AACR’s platform on June 22:

In severe cases of SARS-CoV-2 infections, the immune system has been hyper-activated, triggering a cytokine release storm (CRS). CRS is body’s excessive immunological response against infection that may ultimately lead to organ failure. Cytokine storms are a common complication of Covid-19 and can also occur after cancer immunotherapy treatment. 

When an individual gets infected by SARS-CoV-2, their immune system starts producing antibodies against viral antigens. Therefore, SARS-CoV-2 infection can be detected by measuring these antibodies in the blood of an individual, possibly also after the individual has cured from the disease.

Pharmatest can measure the levels of multiple cytokines/key inflammation markers that are indicative of pathologic inflammatory response and also SARS-CoV-2 reactive IgG class antibodies from plasma and serum samples.

Mouse models for coronavirus research are available upon request.

More information on cytokine storm and cytokine markers:

Pharmatest Services attends AACR-NCI-EORTC Conference in Boston, MA on October 26 –30 and SITC Annual Meeting 2019 in National Harbor, MD on November 7–10. In both events, Pharmatest publishes novel models and emerging scientific findings from preclinical immuno-oncology studies.

In the AACR-NCI-EORTC conference Pharmatest has the following poster presentations:

• Establishment of a novel prostate cancer bone metastasis model in humanized mice and early efficacy results of pembrolizumab. Late-breaking poster A148 on Sunday, October 27.
• Establishment of primary tumor models of TNBC and ER+/HER2- breast cancer in humanized mice and validation of pembrolizumab efficacy. Poster B143 on Monday, October 28.
• Lack of immunotherapy efficacy in a syngeneic bone metastasis model of triple-negative breast cancer. Poster B144 on Monday, October 28.

In the SITC Annual Meeting 2019 Pharmatest has the following poster presentation:

• Pitfalls in preclinical development of immunotherapies for ER+ breast cancer: estrogen as an immunomodulator potentially influencing pembrolizumab efficacy in a breast cancer model in humanized mice. Poster P284, presented on Saturday, November 9.

Shareholders of Pharmatest have elected Dr. Joy Wolfram as a new board member. Dr. Wolfram is Assistant Professor at the renowned Mayo Clinic, where she is the director of the Nanomedicine and Extracellular Vesicles Lab and leads a research group focusing on nanotechnology in cancer.

Dr. Wolfram received her master's degree in biology from the University of Helsinki in Finland and completed her Ph.D. in Nanoscience and Technology at the University of Chinese Academy of Sciences in Beijing, China. She earned her way to the Forbes 30 under 30 in healthcare in 2019 and has received more than 25 scientific awards from seven different countries.

Pharmatest Services attends Annual Meeting of The American Society for Bone and Mineral Research (ASBMR) that will be held in Orlando, FL, USA on September 20 – 23, 2019. Pharmatest attends the event with a booth (#429) and has 6 scientific presentations.

Pharmatest Services has published an invited review article about preclinical bone metastasis models and a research article about the first humanized mouse model of bone metastasis. Humanized mouse models allow confirming efficacy of novel immunotherapies in bone metastatic microenvironment.

Pharmatest Services is a CRO that offers preclinical efficacy services in the fields of oncology and skeletal diseases. In oncology Pharmatest has been the global leading expert in bone metastasis models since 2005.

Pharmatest has recently published the following two scientific papers:

Pharmatest Services attends Annual Meeting of American Association for Cancer Research (AACR) held in Atlanta, Georgia, USA on March 30 – April 3, 2019. Pharmatest attends the event with a booth (#4730) and is presenting 8 scientific presentations.

Pharmatest Services (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. The Annual Meeting of AACR is the leading scientific event in the field of cancer research globally.

This year in AACR Pharmatest presents the following 8 scientific presentations:

• Poster ID 2007: Validation of a preclinical model for bone metastatic triple negative breast cancer. Poster presentation on Monday April 1 at 1:00 PM – 5:00 PM by Justyna Zdrojewska, section 7, poster board 15. (Collaboration with Polyphor Ltd, Allschwil, Switzerland)
• Poster ID 2161:  In vitro osteoblast assays for studying the effects of cancer therapeutics on bone biology. Poster presentation on Monday April 1 at 1:00 PM - 5:00 PM by Jenni Mäki-Jouppila, section 13, poster board 12.
• Poster ID 2814: Systemic and local syngeneic bone metastasis models for immuno-oncology drug development. Poster presentation Tuesday April 2 8:00 AM - 12:00 PM by Tiina Kähkönen, section 3, poster board 30. (Collaboration with Bayer AG, Berlin, Germany)
• Poster ID 3936: Efficacy of single agent radium-223 in the syngeneic MBT-2 bladder cancer bone growth model in mice. Poster presentation on Tuesday April 2 at 1:00 PM - 5:00 PM by Tiina Kähkönen, section 15, poster board 17. (Collaboration with Aurexel Life Sciences Ltd., Askainen, Finland; Vincit Oy, Turku, Finland and Bayer AG, Berlin, Germany)
• Poster ID 4588: Characterization of anti-CTLA-4 effects on tumor growth and immune microenvironment in a syngeneic CT26.WT colon carcinoma mouse model. Poster presentation on Wednesday April 3 8:00 AM - 12:00 PM by Jenni Mäki-Jouppila, section 4, poster board 12. (Collaboration with OracleBio, North Lanarkshire, Scotland, UK and BioSiteHisto, Tampere, Finland)
• Poster ID 4614: Establishment of a HER2 positive breast cancer bone metastasis model for validation of novel therapies. Poster presentation on Wednesday April 3 at 8:00 AM - 12:00 PM by Tiina Kähkönen, section 6, poster board 9. (Collaboration with Bayer AS, Oslo, Norway)
• Poster ID 4616: Establishment of a metastatic orthotopic model of pancreatic ductal adenocarcinoma (PDAC) for drug development. Poster presentation on Wednesday April 3 at 8:00 AM - 12:00 by Justyna Zdrojewska, section 6, poster board 11. (Collaboration with Pharmaxis, New South Wales, Australia)
• Poster ID 4850: The relevance of using proper preclinical models when developing therapeutics for localized or bone metastatic prostate cancer. Poster presentation on Wednesday April 3 at 8:00 AM – 12:00 PM by Jenni Bernoulli, section 15, poster board 8.

Pharmatest has announced the list of events where Pharmatest representatives will attend during 2019. The first events include immuno-oncology seminars in San Francisco on January 22 and San Diego on January 28, and Tumor Models event organized by Hanson Wade in San Francisco on January 23 – 24.

Pharmatest Services is a CRO that offers preclinical efficacy services in the fields of oncology and skeletal diseases. In oncology Pharmatest has been a pioneer in offering bone metastasis models since 2005, and is today the global leader in the field.

The list of events where Pharmatest representatives will attend during 2019 can be found here. The list includes scientific meetings and conventions, and the previously announced immuno-oncology seminars organized by Pharmatest together with our partners.

The first events include immuno-oncology seminars in San Francisco on January 22 and San Diego on January 28, and Tumor Models event organized by Hanson Wade in San Francisco on January 23 – 24. In the Tumor Models event Pharmatest has a booth and the following scientific presentations:

- Oral presentation on January 23 at 4.15 pm titled “Importance of the microenvironment in evaluating IO therapy response – case studies from bone metastasis models in humanized mice”.

- Two poster presentations titled:

• “Characterization of tumor-infiltrating immune cells and the efficacy of pembrolizumab in preclinical models of primary and bone metastatic triple-negative breast cancer”.
•  “Systemic and local syngeneic bone metastasis models for immuno-oncology drug development”.

Pharmatest Services arranges an immuno-oncology seminar series about humanized mouse models during 2019. The first seminars are part of the Biocom seminar series and they will be held in San Francisco on January 22 and in San Diego on January 28.

A large amount of immunotherapies are currently under development, and reliable preclinical models are needed to confirm their efficacy before entering clinical trials. The Pharmatest 2019 seminar series includes speakers from many of our partners and covers extensively the utility of humanized mouse models in oncology.

Pharmatest has been the leading expert and provider of bone metastasis models for over 10 years. In the seminars Pharmatest will present humanized mouse models of bone metastasis, showcasing how immunotherapies can affect differentially tumor growth in metastatic sites than in primary tumors, demonstrating the importance of confirming compound efficacy in relevant metastasis models.

The following five seminars have been confirmed for 2019:

Pharmatest Services attends ASBMR Annual Meeting in Montreal, Canada on September 28 – October 1, 2018. In ASBMR Pharmatest launches two new services, a preclinical mouse model of osteogenesis imperfecta and clinical bone marker measurement services.

Pharmatest Services (Pharmatest) is a CRO that offers preclinical efficacy services in the fields of oncology and skeletal diseases. In skeletal diseases Pharmatest offers bone cell culture models and animal models of osteoporosis and osteoarthritis.

Pharmatest Services attends Annual Meeting of The American Society for Bone and Mineral Research (ASBMR) that will be held in Montreal, Canada on September 28 – October 1, 2018. Pharmatest attends the event with a booth (#217) and has 4 scientific presentations.

Pharmatest Services attends Annual Meeting of American Association for Cancer Research (AACR) held in Chicago, Illinois, USA on April 14 – 18, 2018. Pharmatest attends the event with a booth (#3640) and is presenting 8 scientific presentations.

Pharmatest Services (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. The Annual Meeting of AACR is the leading scientific event in the field of cancer research globally.

This year in AACR Pharmatest presents the following 8 scientific presentations:

-       Poster ID 709: Anti-PD-1 therapy reduces bone lesion growth in a novel syngeneic bladder cancer bone metastasis model. Poster presentation on Sunday April 15 at 1:00 PM - 5:00 PM by Tiina Kähkönen, section 33, poster board 6. (Collaboration with Bayer AG, Berlin, Germany).

-       Poster ID 838: Synergistic in vivo activity of the ATR inhibitor BAY 1895344 in combination with the targeted alpha therapy radium-223 dichloride in a preclinical tumor model mimicking bone metastatic castration-resistant prostate cancer (mCRPC). Poster presentation on Sunday April 15 at 1:00 pm – 5:00 pm by Mari Suominen, Section 39, poster board 1. (Collaboration with Bayer AG, Berlin, Germany).

-       Poster ID 1158: Phenotypic screening using AMIDA identifies different drug responses in breast and prostate cancer cell lines in an organotypic cell culture model. Poster presentation on Monday April 16 at 8:00 AM - 12:00 PM by Katja Fagerlund, section 6, poster board 15. (Collaboration with University of Turku, Turku, Finland).

-       Poster ID 1677: Differential efficacy of PD-1 targeted immunomodulation in preclinical models of primary and bone metastatic triple-negative breast cancer. Poster presentation on Monday April 16 at 8:00 AM - 12:00 PM by Tiina Kähkönen, section 31, poster board 2. (Collaboration with Taconic Biosciences, Rensselaer, NY and BioSiteHisto Ltd, Tampere, Finland).

-       Poster ID 1738: PD-1/PD-L1 expression and tumor-infiltrating immune cells in triple-negative breast cancer: Characterization of preclinical primary tumor and bone metastasis models in humanized mice. Poster presentation on Monday April 16 at 8:00 AM - 12:00 PM by Jenni Bernoulli from Pharmatest and Philip Dube from Taconic Biosciences, section 33, poster board 3. (Collaboration with Taconic Biosciences, Rensselaer, NY and BioSiteHisto Ltd, Tampere, Finland).

-       Poster ID 1162: Castration-resistant prostate cancer bone metastasis model to assess new therapeutics. Poster presentation on Monday April 16 at 8:00 AM - 12:00 PM by Mari Suominen, section 6, poster board 19. (Collaboration with Bayer AG, Berlin, Germany).

-       Poster ID 2684: Drug sensitivity profiling of BT-474 breast cancer cell line for identification of novel therapies targeting HER2-positive breast cancer. Poster presentation on Monday April 16 at 1:00 PM - 5:00 PM by Jenni Mäki-Jouppila, section 30, poster board 24. (Collaboration with Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland).

-     Poster ID 3859: Hormone receptor and HER2/HER3 expression in preclinical breast cancer models of primary tumor and bone metastasis. Poster presentation on Tuesday April 17 at 8:00 AM - 12:00 PM by Jenni Bernoulli, section 36, poster board 2. (Collaboration with Taconic Biosciences, Rensselaer, NY and BioSiteHisto Ltd, Tampere, Finland).

Pharmatest has announced the list of events where staff of Pharmatest will attend during 2018. The first events will be an educational seminar held in San Diego on Jan 23 in an event organized by BIOCOM, followed by the Tumor Models event organized by Hanson Wade in San Francisco on Jan 24 – 25.

Pharmatest Services (Pharmatest) is a CRO that offers preclinical efficacy services in the fields of oncology and skeletal diseases. In oncology Pharmatest has been a pioneer in offering bone metastasis models since 2005, and is today the global leader in the field.

Pharmatest Services has successfully worked with radioactive compounds for almost a decade. Recent scientific publication in collaboration with Bayer shows an example of the strong expertise of Pharmatest in testing efficacy of radiopharmaceuticals in preclinical oncology models.

Pharmatest Services (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. In oncology Pharmatest has strong expertise in bone metastasis models.

Pharmatest Services attends Annual Meeting of The American Society for Bone and Mineral Research (ASBMR) that will be held in Denver, CO, USA on September 8 – 11, 2017. Pharmatest attends the event with a booth (#135) and has 5 scientific presentations.

Pharmatest Services is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. ASBMR Annual Meeting is the leading scientific event in the field of bone research globally.

This year Pharmatest attends ASBMR with the following five scientific presentations:

- Active human immune system induces more severe osteoblastic bone reaction in a humanized mouse model of breast cancer bone metastasis. Oral presentation #1052 on Saturday September 9 at5.45 – 6.00 pm by Tiina Kähkönen, Four Seasons Ballroom I, Colorado Convention Center (collaboration with Taconic Biosciences, USA).

- Bone phenotype of human immune system engrafted mice. Late-breaking poster presentation #LB-SU0359 by Tiina Kähkönen on Sunday, September 10 at 12.30 – 2.30 pm (collaboration withTaconic Biosciences, USA).

- PF708, a therapeutic equivalent and biosimilar candidate to Forteo (teriparatide), demonstrates nonclinical efficacy equivalence to the reference product in the treatment of established osteopenia in adult ovariectomized rats. Poster presentation #SU0317 by Jukka Morko on Sunday, September 10 at 12.30 – 2.30 pm (collaboration with Pfenex Inc., USA).

- Effects of estrogen removal by ovariectomy on growth of human MCF-7 breast cancer cells in bone. Poster presentation #MO0432 by Tiina Kähkönen on Monday, September 11 at 12.00 – 2:00 pm.

- Suitability of various non-Invasive imaging techniques to analyze bone, muscle and fat tissues in ovariectomized mice. Poster presentation #MO0688 by Jukka Vääräniemi on Monday, September 11 at 12.00 – 2.00 pm(collaboration withAlizé Pharma III SAS, France).

Pharmatest Services LLC arranges an educational seminar titled “Significance of Bone Metastases and Targeting Tumor, Bone and Immune System” in hotel Boston Marriott Copley Place in Boston, MA, on September 6 at 8.00 – 10.30 am.

A very large amount of oncology drugs still fail in clinical trials due to poor efficacy. One important reason for this is that compound efficacy is not confirmed in clinically relevant preclinical metastasis models before entering clinical trials. This would be important because the metastatic microenvironment changes tumor properties and induces drug resistance.

This educational seminar highlights significance of bone metastases in clinical and preclinical aspects. Keynote speaker of the seminar will be Dr. Matthew Smith from Massachusetts General Hospital Cancer Center, and other speakers will be from MassBio, Taconic Biosciences and Pharmatest.

Jussi Halleen, CEO of Pharmatest comments: “It is our mission to decrease the currently very high failure rates of oncology drugs in clinical trials, and we want to emphasize the importance of confirming compound efficacy in preclinical metastasis models to achieve this goal”.

Pharmatest Services Ltd attends Annual Meeting of American Association for Cancer Research (AACR) held in Washington, D.C., USA on April 1 – 5, 2017. Pharmatest attends the event with a booth (#3538) and is involved in 8 scientific presentations.

Pharmatest Services Ltd has joined two California-based organizations Biocom and Science Exchange. Biocom is the largest life science organization in California, and Science Exchange is the leading marketplace for scientific research. By joining Biocom and Science Exchange Pharmatest expects to find new customers and increase further its growing US sales.

Pharmatest Services Ltd (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. Pharmatest opened its first US sales office in Boston in early 2013 and its second sales office in San Diego in July 2016. Joining Biocom and Science Exchange is the next step in increasing investments in US marketing for Pharmatest.

Pharmatest Services Ltd attends the Tumor Models conference in San Francisco, CA, on January 24 – 26. Pharmatest is sponsoring the conference and holds a scientific oral presentation and poster presentation in the event.

Pharmatest Services Ltd attends the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics that will be held in Munich, Germany on November 29 – December 2, 2016. Pharmatest presents two scientific poster presentations in the conference.

Pharmatest has started a successful collaboration in preclinical studies with one of the world’s leading CROs. The collaboration with Envigo includes the provision of specialised bone safety assessment to support regulatory preclinical studies for novel therapies.

Pharmatest Services Ltd has purchased two new equipment for bone imaging with most advanced latest technologies, the SkyScan 1276 high resolution desktop in vivo µCT system of Bruker, and the Faxitron UltraFocus DXA digital radiography system of DatecMedico.

Pharmatest Services Ltd (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. Bone imaging has an important role in the services offered by Pharmatest.

Pharmatest Services Ltd attends Annual Meeting of The American Society for Bone and Mineral Research (ASBMR) that will be held in Atlanta, GA, USA on September 16 – 19, 2016. Pharmatest has four scientific presentations in the meeting and we welcome everyone to visit our booth #109.

Pharmatest Services Ltd (Pharmatest) has opened new US sales offices in San Diego, CA, and Concord, MA near Boston. At the same time Pharmatest signed a service agreement with Regus, allowing Pharmatest to use the wide global network of Regus offices and business lounges.

Pharmatest is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. Regus is a multinational corporation that provides a global workspace, including office space and business lounges in 3000 locations worldwide.

Pharmatest started its current US sales strategy by opening its first US sales office in Boston area in early 2013. After that Pharmatest has increased its annual US sales by 4-fold, and the number of new US customer contacts by 6-fold.

The new US sales offices will have an important role for contacting and serving customers in Boston and San Diego areas that are both central locations of pharmaceutical industry in US. The new service agreement with Regus provides an excellent opportunity for Pharmatest to contact and serve customers in multiple locations in the US and elsewhere in the world.

Jussi Halleen, CEO of Pharmatest comments: “Increasing US sales remains one major goal of Pharmatest for the coming years. The US sales strategy that we started in 2013 has already shown its power. We have performed best possible activities and succeeded perfectly in them so far, and now we have taken the next steps to further boost our US sales. I am extremely happy with our new sales offices and the agreement with Regus that will have an important role in achieving this goal.”

Pharmatest Services Ltd attends 4^th Annual Tumor Models conference in Boston, MA, on July 19 – 21. Pharmatest is sponsoring the conference and holds a scientific oral presentation and poster presentation in the event. The oral presentation is taking place in the afternoon of July 21.

Pharmatest Services Ltd releases three White Papers during 2016. The first White Paper was released before the AACR Annual Meeting on April. The second White Paper will be released before the Hanson Wade Tumor Models event on July and the third before the ASBMR Annual Meeting on September.

Pharmatest Services Ltd (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases.

Pharmatest Services Ltd attends Annual Meeting of American Association for Cancer Research (AACR) held in New Orleans, LA, USA on April 16 – 20, 2016. Pharmatest attends the event with a booth (#1524) and is involved in 8 scientific poster presentations.

Pharmatest Services Ltd attends the ORS Annual Meeting in Orlando, Florida, on March 5 – 8, and the TRI-CON event in San Francisco, California, on March 6 – 11. Pharmatest has scientific poster presentations in both events.

Pharmatest Services Ltd (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases.

Pharmatest Services Ltd has finalized the list of events that the company will attend during 2016. The list includes 16 events, of which 3 are attended with a booth. The number of events is substantially higher than in 2015 (including 12 attended events).

After several years of profitable growth Pharmatest will increase its staff amount by hiring four new employees in early 2016. The turnover of Pharmatest increased by 30% in 2015 compared with 2014, and the growth rate is expected to increase further during 2016 and beyond.

Pharmatest Services Ltd and Valirx Plc have signed a 3-year collaboration agreement related to the proprietary GeneICE technology of Valirx. During the project Pharmatest will be responsible for developing GeneICE products and testing their efficacy in Pharmatest’s preclinical cancer models.

Pharmatest Services Ltd attends the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics that will be held in Boston, MA, USA on November 5 – 9, 2015. Pharmatest presents two scientific poster presentations in the conference.

Together with its European partners Pharmatest Services Ltd has received two positive funding decisions for its R&D projects, one from the Eurostars-program and the other from the EuroTransBio program of EU. Both fundings are for 3-year projects and include developing new preclinical efficacy models of oncology.

Pharmatest Services Ltd attends Annual Meeting of The American Society for Bone and Mineral Research (ASBMR) that will be held in Seattle, WA, USA on October 9 – 12, 2015. Pharmatest has four scientific presentations in the meeting and welcomes everyone to visit our booth #320.

Pharmatest Services Ltd attends Tumor Models event of Hanson Wade held in Boston, MA, USA, on July 21 – 23. Pharmatest has a sponsored talk and three poster presentations in the event, and welcomes everyone to visit our booth.

Pharmatest will be attending the 2015 Osteoarthritis Research Society International (OARSI) World Congress in Seattle, WA, USA on April 30 - May 3, 2015.

Pharmatest Services Ltd attends Cancer-Induced Bone Disease (CIBD) meeting held in parallel with the ECTS-IBMS meeting in Rotterdam, The Netherlands, on April 25 – 28. Pharmatest has three scientific presentations in the event.

Pharmatest Services Ltd (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. CIBD represents a major clinical problem with bone metastases developing in 80% of advanced breast and prostate cancer patients, leading to significant morbidity.

Pharmatest attends CIBD meeting with the following three scientific presentations:

Pharmatest Services Ltd has published a new scientific review article “Importance of microenvironment in preclinical models of breast and prostate cancer”. The article was written in collaboration with University of Turku and published in “World Journal of Pharmacology” after invitation from the Journal.

Pharmatest Services Ltd (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. In oncology, Pharmatest is experienced with clinically predictive orthotopic and metastasis models, and especially models of bone metastasis.

Pharmatest decided to accept invitation of the Journal because it is our mission to reduce the amount of drug candidates failing in clinical trials. The majority of cancer drugs entering clinical trials fail to reach the market due to poor efficacy, and Pharmatest wanted to highlight the importance for using correctly selected clinically predictive preclinical efficacy models to improve the situation.

Pharmatest Services Ltd attends Annual Meeting of American Association for Cancer Research (AACR) held in Philadelphia, PA, USA on April 18 – 22, 2015. Pharmatest attends the event with a booth (#1641) and three scientific presentations.

Pharmatest Services Ltd (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. The Annual Meeting of AACR is the leading scientific event in the field of cancer research globally, with over 17,000 expected participants from 60 countries.

Pharmatest Services Ltd has updated the list of events that the company will attend during 2015. The list includes 11 events, of which 8 are attended with scientific presentations and 3 are attended with a booth.

Pharmatest Services Ltd attends the European Association of Urology (EAU) congress held in Madrid, Spain on March 20 – 24, 2015. Pharmatest attends the event with two scientific presentations.

Pharmatest Services Ltd (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. EAU congress is Europe’s largest annual event in urology, with over 14,000 expected participants from more than 100 countries.

This year Pharmatest attends EAU with the following two scientific presentations that describe recent results from its R&D pipeline:

Pharmatest Services Ltd attends Cambridge Healthtech Institute’s third annual conference on “Predictive Preclinical Models in Oncology” that will be held in the Moscone North Convention Center in San Francisco, CA, on February 16 – 18. Pharmatest has two scientific presentations in the conference and welcomes everyone to visit our booth #100.

Pharmatest Services Ltd attends 26^th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics that will be held in Barcelona, Spain on November 18 – 21, 2014. In the symposium Pharmatest presents novel data with Bayer Healthcare about efficacy and mode of action of radium-223 dichloride in a mouse model of prostate cancer bone metastasis.

Pharmatest is presenting new exciting data at the meeting in collaboration with Bayer Pharma AG. The efficacy and mode-of-action of newly approved prostate cancer drug Xofigo® was studied in an osteoblastic prostate cancer bone metastasis model. Radium-223 dichloride therapy exhibits a dual mode-of-action that impacts on tumor growth and on tumor-induced bone reaction, both important players in the destructive vicious cycle of osteoblastic bone metastasis in prostate cancer.

Poster handout will be available here after the start of the poster session:

Pharmatest Services Ltd attends Annual Meeting of The American Society for Bone and Mineral Research (ASBMR) that will be held in Houston, TX, USA on September 12 – 15, 2014. Pharmatest has three scientific presentations in the meeting and welcomes everyone to visit our booth #220.

Pharmatest will be attending the 13th Annual World Pharma Congress in Boston, MA, held on May 21-23, 2014.

In the event Pharmatest has a poster presentation and an invited oral presentation in the conference “In Vitro Tumor Models”. The presentation is titled “Culturing Cancer Cells on Myoma Tissue: Development of a Novel Fully Human Organotypic 3D Invasion Model”, and the oral presentation is scheduled on Thursday May 22 at 5:15 pm (“Selected Poster Presentations” in the program). 

Pharmatest will be attending the 2014 OARSI World Congress in Paris, France on April 24-27, 2014.

Pharmatest attends the congress with a scientific presentation that characterizes the effects of intra-articular rhBMP-7 treatment on the development of posttraumatic OA.

Presentation: Intra-articular treatment with recombinant human bone morphogenetic protein 7 (BMP-7) attenuates the development of osteoarthritis in a surgically induced rat model.

Pharmatest Services Ltd attends Annual Meeting of American Association for Cancer Research (AACR) held in San Diego, CA, USA on April 5 – 9, 2014. Pharmatest attends the event with a booth and scientific presentations and launches new service products in the meeting.

Pharmatest Services Ltd (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. The Annual Meeting of AACR is the leading scientific event in the field of cancer research globally, with over 17,000 expected participants from 60 countries.

Pharmatest to attend High-Content Analysis and Physiologically-Relevant Cellular Models for Drug Discovery meeting on February 19-20, 2014 in San Diego Marriott La Jolla, La Jolla, CA, USA.

Pharmatest will be attending Predictive Preclinical Models in Oncology meeting on February 10-12, 2014 in Moscone North Convention Center, San Francisco, CA, USA.

Pharmatest Services Ltd attends 13^th international conference on cancer-induced bone disease (CIBD) held in Miami, FL, USA on November 6 – 9, 2013. In the conference Pharmatest presents scientific presentations that demonstrate efficacy of customer compounds for treating CIBD.

About half of patients that die from cancer have bone involvement. CIBD develops commonly in many cancers such as breast, prostate and lung cancer and multiple myeloma, and it can also be induced by treatments of primary cancer such as with glucocorticoids, estrogen or androgen deprivation, or chemotherapy-induced ovarian failure.

Pharmatest Services Ltd (Pharmatest) is a contract research organization (CRO) that offers preclinical efficacy services for the pharmaceutical industry in the fields of skeletal diseases and oncology, including high quality research models that are clinically predictive for CIBD. The International Conference on CIBD is the leading scientific event concentrating on CIBD research organized annually by the International Bone and Mineral Society (IBMS).

Pharmatest attends the CIBD conference with two scientific presentations that demonstrate efficacy of customer compounds for treating CIBD. The studies described in the presentations were performed in collaboration with Bayer Pharma AG related to breast cancer and Virobay Inc related to multiple myeloma.

[Updated October 4, 2013] Turku, Finland -based CRO Pharmatest Services Ltd launches new fully validated preclinical efficacy models for osteoarthritis that were developed in a Eurostars-funded project during 2009 – 2013.  The validation results will be presented in the ASBMR annual meeting in Baltimore, MD, during October 4 – 7.

Osteoarthritis (OA) is the most common joint disease and among the most common causes of chronic pain and disability in older people, affecting 12.6% of total population in Western countries. No disease modifying treatment options for OA are currently available, and development of OA drugs is of increasing interest to the pharmaceutical industry.

Pharmatest Services Ltd (Pharmatest) is a contract research organization (CRO) that offers preclinical efficacy services for the pharmaceutical industry in the fields of skeletal diseases and oncology. Annual meeting of the American Society for Bone and Mineral Research (ASBMR) is the globally leading scientific event in bone research.

Pharmatest Services Ltd (Pharmatest) has been the preferred provider of Bayer Pharma AG (Bayer) since 2010. The results of several projects performed at Pharmatest regarding the newly FDA approved cancer drug Xofigo were published last week, and Bayer says to be impressed about the high quality of the work performed by Pharmatest during the collaboration.

Pharmatest offers clinically predictive preclinical efficacy services for the pharmaceutical industry for testing their drug candidates in the fields of oncology and skeletal diseases. Pharmatest has been the preferred provider of Bayer since 2010, after several years of successful collaboration.

[Updated April 18, 2013] Pharmatest is proud to inform development of four new rat osteoarthritis models that will be soon available as service products. The new models will be presented for the first time in the OARSI Meeting in Philadelphia, Pennsylvania on April 18-21, 2013, where we will give a poster presentation titled

“Degenerative changes in knee joints as determined by OARSI rat scoring system and osteoarthritis-related joint pain in surgically and chemically induced rat models of osteoarthritis” (Poster 112)

[Updated April 9, 2013]

Pharmatest will be attending the key annual event in cancer research, AACR Annual Meeting in Washington DC, USA, April 6-10.

[Updated March 21, 2013] Turku, Finland-based Pharmatest Services Ltd (Pharmatest) has opened a new US sales office in Cambridge, MA near Boston. The new office provides an excellent opportunity for Pharmatest to contact and serve customers, with a large number of potential customers located in the Boston area.

Pharmatest offers clinically predictive preclinical efficacy services for the pharmaceutical industry for testing their drug candidates in the fields of oncology and skeletal diseases. Cambridge, MA is one of the central locations of the pharmaceutical industry in America. The Pharmatest sales office is located in the Cambridge Innovation Center, which is centrally located amongst a large number of potential customers.

Despite the fact that Pharmatest has not had any direct US sales activities before, the company has already a wide customer base in the US. With the new sales office and increased US sales and marketing efforts Pharmatest expects to rapidly grow the number of US customers and US sales figures.

In combination with the opening of the sales office Pharmatest hired Andrew Heiniluoma as the US sales representative with responsibility for the Cambridge office. Andrew says: “I am very excited for the opportunity to work for Pharmatest. Cambridge is a perfect site for a US sales office, and the Boston area is unique in the US in terms of the presence of the pharma industry, providing an outstanding opportunity for attracting new customers for Pharmatest.”

Jussi Halleen, CEO of Pharmatest comments: “USA has the biggest market potential for our services and we now have a clear strategy to focus on increasing our US market share. We are very happy to have Andy on board in Cambridge, which allows us to get closer to our customers. I am convinced that this will boost our US revenues in the coming years.”

The Turku-based company Pharmatest Services Ltd (Pharmatest) has signed a Master Service Agreement with the London AIM-listed cancer drug development company Valirx Plc (Valirx). The agreement makes Pharmatest preferred provider of preclinical efficacy testing services for Valirx in its cancer drug development programs.

Pharmatest offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. Valirx is developing new cancer drugs and has tested their compounds in several models of Pharmatest. After about one year of customer relationship Valirx decided to sign a long-term Master Service Agreement with Pharmatest that gives Pharmatest preferred provider status for the services that it offers.

Valirx expects that the agreement will help them especially in selecting the most effective compounds from their GeneICE program and confirming correct indications for the selected compounds for planning subsequent clinical trials. Satu Vainikka, CEO of Valirx says: “We have been very pleased about the quality of the services that Pharmatest provides and we are convinced that this partnership will significantly benefit our cancer drug development programs.”

Jussi Halleen, CEO of Pharmatest comments: “We are very happy to sign this agreement with Valirx to follow our preferred provider partnership with Bayer Healthcare that was signed in 2010. These partnerships show that we are on the right track in developing our services.”